1	2	3
	(4) M/s. Lyka Labs.	Pending
	(5) M/s. Merind	Pending
(iii) *Calcutta High Court*	(1) M/s. Carews	Pending
	(2) M/s. Dolphin	Pending
(iv) *Ahmedabad High Court*	(1) M/s. Cadila	Pending

The Writ Petitions are mainly against the prices fixed by the Govt. and/or notice for recovery of the tentative liability of the Company, issued by the Govt. The Counter-affidavits have yet to be filed by the Govt. in the case of M|s. Lika Labs., M/s. Merind, M|s. Dolphin and M(s. Cadila and these are being expedited.

(h) and (i) The matter is being pursued.

Price of Flucort Range formulations

3052. SHRIMATI RATAN KUMARI: Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that contrary to the Government decision price of Flucort Range of formulations has been increased by using a small scale sector unit as an intermediary;

(b) if so, the name of the small scale unit and the percentage of price increase in each pack and strength;

(c) what is the price being charged on Flucort range of finished medicines based on the stocks with chemists and since when price increase has been put into effect;

(d) whether it is a fact that new price amounts to over-charging the consumer by rupees four crores per annum; and

(e) what steps Government have taken to pass orders for seizure of stock and prosecution of the management for open de finance?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) No such instance has come to the notice of Government.

(c) to (e) The State Drugs Controller has been asked to verify as to when the company had implemented the prices fixed by the Government in respect of Flucort range of formulations.

Indication for using Glipizide

3053. SHRI ANANT RAM JAISWAL: Will the PRIME MINISTER be pleased to refer to the answer to Unstarred Question 1669 given in the Rajya Sabha on the 12th September, 1991 and state:

(a) what is the indication for which Glipizide is used;

(b) what are the names of the producers of Glipizide and what was the production of each during the last three years year-wise;

(c) whether it is also a fact that Glipizide is under price control;

(d) whether it is also a fact that Glybenclamide is also used for same indication;

(e) if so, on what basis this drug has been decontrolled and what are the criteria adopted;

(f) whether it is also a fact that Pentoxyphylline is outside price control;

(g) if so, on what basis;

(h) what are the names of drugs of this producer which are outside price control and what are the names of other producers of these drugs; and

(i) what was the production of each including the producer in question during the last three years, year-wise?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) Glipizide is used in the treatment of diabeties.

(b) There is no known production of bulk drug Glipizide in the country.

(c) and (d) Yes, Sir.

(e) The requisite information has already been given in reply to Rajya Sabha Unstarred Question No. 1322 answered on 5-12-1991.

(f) Yes, Sir.

(g) The inclusion/exclusion of bulk drugs under price control under DPCO, 1987 is mainly based on the recommendations made by the Kelkar Committee in its Main as well as Supplementary Report which were accepted by the then Government.

(h) and (i) The information sought for is voluminous. The time and labour involved in collecting the same will not be commensurate with the results likely to be achieved.

List of Essential Drugs

3054. DR. NARREDDY THULASI REDDY: Will the PRIME MINISTER be pleased to state:

(a) whether the list of essential drugs for India has been prepared; and

(b) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) For the purpose of price control, a list of 143 drugs falling under two categories (Category-I consisting of drugs used in National Health Programme and Category-II consisting of other drugs considered as essential) is being operated. This list is presently under review as part of review of Drug Policy.

Grant of Stay to maintain price of Drugs

3055. DR. RATNAKAR PANDEY: Will the PRIME MINISTER be pleased to state:

(a) what was the ground on which Delhi High Court granted stay to maintain prices in the case of Cyanamid V/s. Union of India;

(b) whether it is a fact that stay was granted on certain conditions; and

(c) if so, the details thereof?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) to (c) A copy of the Delhi High Court's order dated 25-11-81 in the case of Cynamid v/s. Union of India is enclosed in the statement.

Statement

Copy of an order dt. 25-11-81 passed by Hon'ble the Chief Justice and Hon'ble Mr. Justice B. N. Kirpal in C. M. No. 1153|81 in C.W. 820|81 re: M|s. Cynamid India Ltd. Vs. UOI etc.

Present: Mr. T. M. Ansari with Mr. S. H. Merchant for the petitioners.

Mrs. Vijaya Rao for the respondents.

C.M. 1153|81

After hearing learned counsel and with their consent, an arrangement has been worked out as an interim measure. We, therefore, confirm, till further orders the interim order made by us on April 20, 1981. The term of the said order are *i.e.* on the undertaking piven on behalf of the petitioner's to maintain *status quo* on the prices prevailing prior to the issue of the impunged notifications the petitioners throngh their counsel further given an undertaking to this court that, in case the petition is dismissed and the rule is discharged the petitioners shall within eight weeks of the dismissal of the petition by this court deposit in this court the difference in the price of the formulations in question for being ultimately deposited in the Drug Prices Equalisation Account. T petitioners through their counsel further given an undertaking that in this cuort the petitioners would not contend or challenge